-
Over 1 million migrants apply for Spain's mass regularisation: PM
-
S. Africa deploys police as anti-migrant protests loom
-
Thousands from Philippine sect protest pro-Duterte senator's graft case
-
Monaco parcel bomb blast wounds Ukrainian oligarch
-
South Africa repatriations top 25,000 ahead of anti-immigrant ultimatum
-
Sweden face France's attacking firepower at the World Cup
-
Taiwan raids tech firms in China AI chip smuggling probe
-
Online same-sex romance series embrace AI 'freedom'
-
Morocco 'unstoppable' says coach after Netherlands thriller
-
New Oxford academic centre symbolises UK's big-donor era
-
Russia's small businesses pay the price of spiralling Ukraine war
-
Trump says Iran meeting set in Qatar, despite uncertainty
-
Paraguay shock Germany as Brazil, Morocco advance at World Cup
-
Morocco down Netherlands to reach World Cup last 16
-
NASA robot mission aiming to rescue space telescope
-
Asian stocks unable to track Wall St higher, yen holds at 40-year low
-
Mouse-that-roared Paraguay savors World Cup win over Germany
-
'We came from nothing': DR Congo dreams of England World Cup upset
-
Taiwan's ageing seaweed harvesters hope younger women wade in
-
Peruvian political heir Fujimori wins presidency
-
Key Venezuela port opens with US aid, as burials begin
-
What to expect as EU small parcel levy kicks in
-
Ambitious Japan search for answers after World Cup exit
-
Nagelsmann says won't 'run away' after Germany World Cup exit
-
How NATO will try to keep Trump happy at Ankara summit
-
Paraguay coach salutes 'extraordinary' World Cup win over Germany
-
Ultra-wealthy Chinese exile in New York sentenced to 30 years for fraud
-
Japan fans stunned as Brazil end their World Cup dream
-
Years on, families bury 68 Indigenous victims of Guatemala civil war
-
'Powerhouse' Haaland leads by example at World Cup: Norway coach Solbakken
-
'Deliberate' Monaco explosion wounds Ukrainian oligarch
-
Sadness and joy as breakaway Catholic group nears schism
-
Paraguay shock Germany, Brazil advance at World Cup
-
HUNTING/HER Headhunter Talk with EnBW Board Member & CHRO Colette Rückert-Hennen
-
SP Industries Inc. Leverages Bioz to Unify Scientific Validation Across Its Portfolio of Leading Brands
-
Apex Mobilizes Drill Rig and Commences 2026 Exploration Program at the Cap Critical Minerals Project
-
Creality Printers Review Site Help Buyers Compare Creality Printers
-
Tenstorrent Sets New Performance Records, Launches TT- Ascalon S, and Expands Across Japan
-
InterContinental Hotels Group PLC Announces Transaction in Own Shares - June 30
-
Guardian Metal Resources PLC Announces Pilot Mountain Pre-Feasibility Study Results
-
Germany dumped out by Paraguay in seismic World Cup shock
-
'I recognized her ring': identifying Venezuela's dead in a makeshift morgue
-
More than 1,000 drones detected since start of World Cup: FBI
-
Tuchel defensive headache as England ready for DR Congo clash
-
Extreme heat warning issued for World Cup host Kansas City
-
US reopens Venezuela port as quake deaths top 1,700
-
Bloodied but unbowed: Sinner, Djokovic survive Wimbledon scares
-
Coach says Japan getting closer to World Cup glory despite defeat
-
Djokovic battles past Wu in 'challenging' Wimbledon first round
-
NBA Grizzlies deal Morant to Portland: report
Study shows how fast kilos return after ending weight-loss drugs
When people stop taking the new generation of weight-loss drugs they pile back on the kilos four times faster than they would after ending diet and exercise regimes, new research found Thursday.
But this was mostly because they lost so much weight in the first place, according to the British researchers who conducted the largest and most up-to-date review of the subject.
A new generation of appetite-suppressing, injectable drugs called GLP-1 agonists have become immensely popular in the last few years, transforming the treatment for obesity and diabetes in many countries.
They have been found to help people lose between 15-20 percent of their body weight.
"This all appears to be a good news story," said Susan Jebb, a public health nutrition scientist at Oxford university and co-author of a new BMJ study.
However, recent data has suggested that "around half of people discontinue these medications within a year," she told a press conference.
This might be because of common side effects such as nausea or the price -- these drugs can cost over $1,000 a month in the US.
So the researchers reviewed 37 studies looking at ceasing different weight-loss drugs, finding that participants regained around 0.4 kilograms a month.
Six of the clinical trials involved semaglutide -- the ingredient used in Novo Nordisk's brands Ozempic and Wegovy -- and tirzepatide used for Eli Lilly's Mounjaro and Zepbound.
While taking these two drugs, the trial participants lost an average of nearly 15 kilograms.
However after stopping the medication, they regained 10 kilograms within a year, which was the longest follow-up period available for these relatively new drugs.
The researchers projected that the participants would return to their original weight in 18 months.
Measurements of heart health, including blood pressure and cholesterol levels, also returned to their original levels after 1.4 years.
People who were instead put on programmes that included diet and exercise -- but not drugs -- lost significantly less weight. However it took an average of four years for them to regain their lost kilos.
This meant that people taking the drugs regained their weight four times faster.
- 'Starting point, not a cure' -
"Greater weight loss tends to result in faster weight regain," lead study author Sam West of Oxford University explained.
But separate analysis showed that weight gain was "consistently faster after medication, regardless of the amount of weight lost in the first place," he added.
This could be because people who have learned to eat more healthily and exercise more often continue to do so even as they regain weight.
Jebb emphasised that GLP-1 drugs "are a really valuable tool in obesity treatment -- but obesity is a chronic relapsing condition."
"One would expect that these treatments need to be continued for life, just in the same way as blood pressure medication," Jebb said.
If this was the case, it would impact how national health systems judge whether these drugs are cost-effective, the researchers emphasised.
"This new data makes it clear they are a starting point, not a cure," said Garron Dodd, a metabolic neuroscience researcher at the University of Melbourne not involved in the study.
"Sustainable treatment will likely require combination approaches, longer-term strategies, and therapies that reshape how the brain interprets energy balance, not just how much people eat," he said.
A.Anderson--AT